Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

OLAYEMI OSIYEMI

Allopathic & Osteopathic Physicians Internal Medicine Infectious Disease

NPI
1063522332
CMS profile
320710
Location
WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$48,699.74

277 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 4 of 6; records 151–200 of 277 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

OLAYEMI OSIYEMI

NPI 1063522332 · CMS profile ID 320710

Allopathic & Osteopathic Physicians / Internal Medicine / Infectious Disease

WEST PALM BEACH, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 6; records 151–200 of 277 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063522332?year=2022&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
OLAYEMI OSIYEMI, NPI 1063522332, CMS profile ID 320710. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 277 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063522332?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). OLAYEMI OSIYEMI, NPI 1063522332, CMS profile ID 320710. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 6; records 151–200 of 277 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063522332?year=2022&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
OLAYEMI OSIYEMI, NPI 1063522332, CMS profile ID 320710, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 6; records 151–200 of 277 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1063522332?year=2022&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

277 matching records · $48,699.74 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 277 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 277.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Gilead Sciences, Inc. $26.4706/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503097 CMS
Merck Sharp & Dohme LLC $22.5806/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944187517 CMS
ViiV Healthcare Company $123.8306/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086267 CMS
Insmed, Inc. $26.5706/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906426113 CMS
Merck Sharp & Dohme LLC $17.6006/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944335953 CMS
Gilead Sciences, Inc. $5.0606/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502943 CMS
Gilead Sciences, Inc. $21.1106/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503001 CMS
Janssen Biotech, Inc. $0.9906/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771197 CMS
Janssen Biotech, Inc. $22.3906/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771201 CMS
ABBVIE INC. $15.3906/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891294239 CMS
ViiV Healthcare Company $17.7806/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086121 CMS
Gilead Sciences, Inc. $2,690.0006/07/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929446329 CMS
ViiV Healthcare Company $29.4606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086027 CMS
ViiV Healthcare Company $6.1606/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086069 CMS
ViiV Healthcare Company $3.1306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086073 CMS
ViiV Healthcare Company $47.1206/02/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086115 CMS
ViiV Healthcare Company $14.5706/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086189 CMS
ViiV Healthcare Company $0.4806/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086331 CMS
Gilead Sciences, Inc. $46.8206/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503135 CMS
Janssen Biotech, Inc. $5.6806/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771015 CMS
Gilead Sciences, Inc. $5.0905/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502951 CMS
Gilead Sciences, Inc. $23.7105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503050 CMS
Merck Sharp & Dohme LLC $16.7205/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944178131 CMS
ViiV Healthcare Company $3,900.0005/25/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086077 CMS
ViiV Healthcare Company $21.4605/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086323 CMS
Theratechnologies Inc. $28.5905/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943967231 CMS
ViiV Healthcare Company $24.5805/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086271 CMS
Janssen Biotech, Inc. $19.8805/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771055 CMS
Janssen Products, LP $65.0005/17/2022 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887107243 CMS
Gilead Sciences, Inc. $5.7305/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502963 CMS
Gilead Sciences, Inc. $24.5505/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503061 CMS
Insmed, Inc. $2.0005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906426607 CMS
Insmed, Inc. $20.8705/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 906436509 CMS
ViiV Healthcare Company $114.3005/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086201 CMS
Janssen Biotech, Inc. $21.4405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771147 CMS
ViiV Healthcare Company $9.0105/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086339 CMS
ViiV Healthcare Company $16.5405/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086197 CMS
ViiV Healthcare Company $0.8005/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944086225 CMS
Theratechnologies Inc. $24.1405/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 943967227 CMS
Gilead Sciences, Inc. $5.6704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502959 CMS
Melinta Therapeutics, LLC $23.2604/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960319443 CMS
Gilead Sciences, Inc. $0.5004/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502877 CMS
Gilead Sciences, Inc. $23.5704/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503045 CMS
Paratek Pharmaceuticals, Inc. $20.8404/20/2022 Food and Beverage No dispute reported Delay: No
Change: CHANGED
06/30/2026 881677293 CMS
Janssen Biotech, Inc. $0.6904/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771215 CMS
Janssen Biotech, Inc. $21.9604/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 885771219 CMS
Gilead Sciences, Inc. $3.2104/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929502927 CMS
Gilead Sciences, Inc. $21.1804/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 929503005 CMS
ABBVIE INC. $13.1204/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891294237 CMS
Merck Sharp & Dohme LLC $1,860.0004/13/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944037505 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59,258.35 308
PY2020 $14,598.83 226
PY2021 $15,340.61 275
PY2022 $48,699.74 277
PY2023 $19,111.52 229
PY2024 $46,813.77 270
PY2025 $43,886.55 221

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $232,203.52 43
PY2024 Principal investigator $330,821.62 47
PY2023 Recipient $1,495.90 9
PY2023 Principal investigator $695,621.91 36
PY2022 Principal investigator $953,615.46 93
PY2021 Recipient $35,684.50 5
PY2021 Principal investigator $3,529,484.17 156
PY2020 Recipient $286.32 1
PY2020 Principal investigator $1,996,291.23 283
PY2019 Recipient $119,885.68 21
PY2019 Principal investigator $814,676.67 206

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

43 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $826.65 12/31/2025 Non-covered Recipient Entity
Triple O Research Institute, P.A
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-na ve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease No dispute reported 06/30/2026 1232934098
Principal investigator 1 ViiV Healthcare Company $10,438.07 11/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315065
Principal investigator 1 ViiV Healthcare Company $5,010.06 11/03/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315655
Principal investigator 1 ViiV Healthcare Company $7,674.18 10/28/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315403
Principal investigator 1 ABBVIE INC. $3,000.00 10/09/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202514733
Principal investigator 1 ViiV Healthcare Company $789.75 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315061
Principal investigator 1 ViiV Healthcare Company $50.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315063
Principal investigator 1 ViiV Healthcare Company $967.95 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315067
Principal investigator 1 ViiV Healthcare Company $2,500.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315069
Principal investigator 1 ViiV Healthcare Company $250.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315071
Principal investigator 1 ViiV Healthcare Company $750.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315397
Principal investigator 1 ViiV Healthcare Company $500.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315399
Principal investigator 1 ViiV Healthcare Company $250.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315405
Principal investigator 1 ViiV Healthcare Company $350.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315407
Principal investigator 1 ViiV Healthcare Company $7,793.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315409
Principal investigator 1 ViiV Healthcare Company $250.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315479
Principal investigator 1 ViiV Healthcare Company $1,940.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315481
Principal investigator 1 ViiV Healthcare Company $1,500.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315483
Principal investigator 1 ViiV Healthcare Company $985.50 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315485
Principal investigator 1 ViiV Healthcare Company $350.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315487
Principal investigator 1 ViiV Healthcare Company $150.00 09/19/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315491
Principal investigator 1 ViiV Healthcare Company $13,178.11 09/15/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315073
Principal investigator 1 ABBVIE INC. $2,403.00 09/03/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202507557
Principal investigator 1 ViiV Healthcare Company $3,997.35 08/27/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315643
Principal investigator 1 ViiV Healthcare Company $9,890.15 08/15/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315489
Principal investigator 1 ABBVIE INC. $24,952.25 08/12/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202504265
Principal investigator 1 ABBVIE INC. $19,920.25 07/28/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500188
Principal investigator 1 ABBVIE INC. $1,291.75 07/28/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202500190
Principal investigator 1 ViiV Healthcare Company $12,226.46 07/24/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315401
Principal investigator 1 ViiV Healthcare Company $337.50 07/18/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315651
Principal investigator 1 ViiV Healthcare Company $2,546.10 07/18/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315653
Principal investigator 1 ViiV Healthcare Company $6,353.77 06/13/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315493
Principal investigator 1 ABBVIE INC. $931.50 06/03/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202487477
Principal investigator 1 ViiV Healthcare Company $41,625.51 05/26/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315075
Principal investigator 1 ABBVIE INC. $1,613.25 05/06/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202481797
Principal investigator 1 ViiV Healthcare Company $9,991.84 04/28/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A PHASE 2B SINGLE ARM, REPEAT DOSE STUDY TO EVALUATE THE PHARMACOKINET No dispute reported 06/30/2026 1190315395
Principal investigator 1 ViiV Healthcare Company $2,806.65 04/16/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315649
Principal investigator 1 ABBVIE INC. $3,962.25 04/03/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202468868
Principal investigator 1 ViiV Healthcare Company $2,403.75 03/07/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315641
Principal investigator 1 ViiV Healthcare Company $13,600.65 03/07/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315645
Principal investigator 1 ABBVIE INC. $1,957.50 02/06/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202448638
Principal investigator 1 ViiV Healthcare Company $5,994.02 01/08/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE
A PHASE 3B, MULTICENTER, SINGLE-ARM, OPEN-LABEL STUDY EVALUATING THE E No dispute reported 06/30/2026 1190315647
Principal investigator 1 ABBVIE INC. $3,894.75 01/02/2025 Non-covered Recipient Entity
TRIPLE O RESEARCH INSTITUTE PA
M19-965 - A Study to Assess Change in Disease Activity Adverse Events and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382 No dispute reported 06/30/2026 1202435039